Peripheral nervous system manifestations of XXXX .

@entity1 @entity129 @entity2756 @entity3001 @entity9144 @entity32242 @entity528 @entity8954 @entity2069 @entity3403 @entity425 @entity281 @entity4432 @entity158 @entity3541 @entity10 @entity221 @entity413 @entity7545
@entity3001 is a @entity7545 that has protean neurologic manifestations involving both the central and peripheral nervous system. The peripheral nervous system manifestations of @entity3001 can be divided chronologically into acute and chronic forms. Within weeks after disease onset, approximately 15% of untreated @entity1 develop an acute Lyme meningoradiculoneuritis with @entity10 , @entity221 , @entity158 , @entity425 , and sensory loss, often associated with @entity129 , usually @entity3541 . Cerebrospinal fluid typically shows lymphocytic pleocytosis, high protein, and normal @entity413 . Diagnosis is made by recognition of characteristic clinical features with a history of preceding exposure and confirmed by serologic evidence of exposure to @entity2069 or by antibody or PCR evidence of cerebrospinal fluid @entity281 . Months to years after onset, rare @entity1 may develop chronic @entity8954 presenting with sensory symptoms or @entity158 . Diagnosis is confirmed by a history of exposure, previous systemic or acute neurologic manifestations of @entity3001 , and serologic evidence of @entity281 . Pathology of @entity4432 reveals @entity528 with perivascular mononuclear infiltration. Eradication of the organism can be achieved with 2 to 4 weeks of @entity2756 for both acute and chronic @entity9144 . Isolated @entity3541 without evidence of cerebrospinal fluid @entity281 can be treated with oral antibiotics such as @entity3403 . Prognosis after therapy is good, but neurologic recovery is slower for chronic than acute Lyme @entity32242 .
